Jazz Pharmaceuticals (JAZZ) Cash from Operations Growth (3y) (2013 - 2026)

Jazz Pharmaceuticals (JAZZ) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Jazz Pharmaceuticals 15.75 Bn 13.91 Bn 934.80 Mn 8.37%

Historic Data

Download Data
DateValue
Mar 31, 2026 8.37%
Dec 31, 2025 1.96%
Sep 30, 2025 4.33%
Jun 30, 2025 -33.57%
Mar 31, 2025 27.17%
Dec 31, 2024 30.89%
Sep 30, 2024 13.31%
Jun 30, 2024 99.56%
Mar 31, 2024 -2.12%
Dec 31, 2023 -3.51%
Sep 30, 2023 6.01%
Jun 30, 2023 17.59%
Mar 31, 2023 5.52%
Dec 31, 2022 57.34%
Sep 30, 2022 7.39%
Jun 30, 2022 26.74%
Mar 31, 2022 1.10%
Dec 31, 2021 -6.59%
Sep 30, 2021 7.36%
Jun 30, 2021 -39.89%